Publications

Antal CE, Hudson AM, Kang E, Zanca C, Wirth C, Stephenson NL, Trotter EW, Gallegos LL, Miller CJ, Furnari FB, Hunter T, Brognard J*, Newton AC*. Cancer-Associated Protein Kinase C Mutations Reveal Kinase's Role as Tumor Suppressor. Cell. 2015 Jan 29;160(3):489-502.* Corresponding authors

Discrepancies in Cancer Genomic Sequencing Highlight Opportunities for Driver Mutation Discovery. Hudson AM, Yates T, Li Y, Trotter EW, Fawdar S, Chapman P, Lorigan P, Biankin AV, Miller C*, Brognard J*. Cancer Res. 2014 Sep 25. pii: canres.1020.2014. [Epub ahead of print]  * Corresponding authors

Marusiak AA, Edwards ZC, Hugo W, Trotter EW, Girotti MR, Stephenson NL, Kong X, Gartside MG, Fawdar S, Hudson A, Breitwieser W, Hayward NK, Marais R, Lo RS, Brognard J (2014). Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat Commun, 5:3901. DOI: 10.1038/ncomms4901

Fawdar S, Trotter EW*, Yayong Li*, Stephenson N, Hanke F, Marusiak AA, Edwards ZC, Ientile S, Waszkowycz B, Miller CJ, Brognard J. Targeted Genetic Dependency Screen Facilitates Efficient Identification of Gain-of-Function Mutations in FGFR4, PAK5, and MAP3K9 in Lung Cancer. In Press at Proceedings of National Academy of Sciences. *Authors contributed equally

Fawdar S, Edward ZC, Brognard J*. Druggable Drivers of Lung Cancer. Oncotarget. 2013 Aug 14. [Epub ahead of print]

Belot A*, Kasher PR*, Trotter EW*, Foray AP, Debaud AL, Rice GI, Szynkiewicz M, Zabot MT, Rouvet I, Bhaskar SS, Daly SB, Dickerson JE, Mayer J, O’Sullivan J, Juillard L, Urquhart JE, Fawdar S, Marusiak AA, Stephenson N, Waszkowycz B, Beresford MW, Biesecker LG, Black GC, ReneÅLe C, Eliaou JF, Fabien N, Ranchin B, Cochat P, Gaffney PM, Lebon P, Malcus C, Crow YJ**, Brognard J**, Bonnefoy N** Protein kinase C δ deficiency causes mendelian systemic lupus erythematosus with B-cell defective apoptosis and hyperproliferation. Arthritis and Rheumatism, May 10 2013 [Epub ahead of print]. *Authors contributed equally and **Corresponding authors.

Brognard J*, Zhang YW, Puto LA,  Hunter T.  Cancer-Associated Loss-of-Function Mutations Implicate DAPK3 as a Tumor-Suppressing Kinase.  Cancer Research, Vol. 71 Issue 8, Apr 15, 2011. Pgs: 3152-61. *Co-Corresponding Author

Brognard J*, Hunter T. Protein Kinase Signalling Networks in Cancer. Current Opinions in Genetics and Devlopment, Vol. 21, Issue 1, February 2011. Pgs.: 4-11. *Co-Corresponding Author

Zhang YW, Brognard J, Coughlin C,You Z, Aslanian A, Manning G, Abraham RT, Hunter T. The F-box Protein Fbx6 Regulates Stability of Chk1 and Cellular Sensitivity to Replication Stress. Molecular Cell Vol 35, August 28, 2009. Pgs: 442-53.

Brognard J, Niederst M, Reyes G, Warfel N, Newton AC.  Common polymorphism in the phosphatase PHLPP2 results in reduced regulation of Akt and Protein Kinase C. Journal of Biological Chemistry, Volume 284, Issue 22, May 29, 2009.  Pgs:15215-23. 

Brognard J, Newton AC. PHLiPPing the switch on Akt and PKC signaling.  Trends in Endocrinology and Metabolism, Vol. 19, Issue 6, August 19th, 2008.  Pgs: 223-230.

Gao T, Brognard J, Newton AC. The phosphatase PHLPP controls the cellular levels of protein kinase C.  Journal of Biological Chemistry, Vol. 283, Issue 10, March 7, 2008.  Pgs: 6300-6311.

Brognard J, Sierecki E, Gao T, Newton AC.  PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Molecular Cell, Vol. 25, March 23, 2007. Pgs: 917-931.  Previewed: Mendoza MC, Blenis J. PHLPPing it off: phosphatases get in the Akt. Molecular Cell, Vol. 25, Mar 23, 2007.  Pgs:798-800.

Tsurutani J, Castillo SS, Brognard J, Granville CA, Zhang C, Gills JJ, Sayyah J, Dennis PA. Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. Carcinogenesis. July 26, 2005. Volume 26 Number 7, Pgs: 1182-95.

Brumbaugh KM, Otterness DM, Geisen C, Oliveira V, Brognard J, Li X, Lejeune F, Tibbetts RS, Maquat LE, Abraham RT. The mRNA surveillance protein, hSMG-1, functions in genotoxic stress response pathways in mammalian cells.  Molecular Cell Vol. 14, June 4, 2004.  Pgs: 585-98.

Castillo SS, Brognard J, Petukhov PA, Zhang C, Tsurutani J, Granville CA, Li M, Jung M, West KA, Gills JG, Kozikowski AP, Dennis PA.  Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Research Vol. 64, Issue 8, April 15, 2004.  Pgs: 2782-2792.

West KA*, Brognard J*, Clark AS, Linnoila IR, Yang X, Swain SM, Harris C, Belinsky S, Dennis PA.  Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells.  Journal of Clinical Investigation Vol. 111, Issue 1, Jan. 2003. Pgs: 81-90.  *Note: Co-First Author PublicationPreviewed:Minna JD. Nicotine exposure and bronchial epithelial cell nicotinic acetylcholine receptor expression in the pathogenesis of lung cancer.  J Clin Invest. 2003 Jan1:pgs 31-3.

Kozikowski AP, Sun H, Brognard J, Dennis PA. Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. Journal American Chemical Society, Feb 5, 2003, Volume125, Issue 5. Pgs:1144-5.

Brognard J, Dennis PA  Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. Cell Death and Differentiation, Vol. 9, Issue 9, Sept. 2002.  Pgs: 893-904

Brognard J, Clark A, Ni Y, Dennis PA  Akt/PKB is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation.  Cancer Research Vol. 61, Issue 10, May 15, 2001.  Pgs: 3986-97 

Patents

  • US Patent #20050272708 Kozikowski AP, Dennis PA, Brognard J, and Sun H: Akt Inhibitors, Pharmaceutical Compositions, and uses Thereof.  Filed: Sept. 3, 2002.  Accepted: Dec. 8, 2005.
  • US Patent Pending 60/667,709 Newton AC, GaoT, Brognard J: Compositions and Methods for Treating Diseases Associated with PHLPP.  Filed: March 31, 2006.